Cipla Ltd

Cipla Ltd maintains a strong liquidity position, with a current ratio of 3.71, indicating the company can easily cover its short-term liabilities with its short-term assets. The company's liquidity_fpt score is high, supported by a cash and equivalents balance of INR 8.75 billion, which provides a buffer against short-term financial obligations. In terms of profitability, Cipla Ltd's return on equity (ROE) of 3.52% and return on assets (ROA) of 2.87% are below the industry median for pharmaceutical companies, suggesting that the company is not generating returns as efficiently as its peers. The operating margin of 16.7% is in line with the industry, but the net margin of 15.2% is slightly below the median, indicating potential pressure from rising costs or competitive pricing. Cipla Ltd's revenue is primarily concentrated in India, with a significant portion of its business derived from domestic markets. The company has a limited presence in international markets, which may expose it to regulatory and currency risks in the Indian healthcare sector. The company's geographic exposure is not diversified, and it does not report significant revenue from other regions. The company's growth trajectory is moderate, with a projected revenue increase of 4.5% in the current fiscal year and 5.2% in the next fiscal year. This growth is supported by a stable operating cash flow of INR 41.34 billion and a capital expenditure of INR 13.49 billion, which suggests the company is investing in its operations to sustain long-term growth. Cipla Ltd's risk assessment indicates a low probability of liquidity and dilution risks. The company's debt-to-equity ratio of 0.02 is well below the industry median, and there are no immediate filing-based flags for liquidity or dilution. The company has not made any recent equity issuances or announced plans for a public offering, and its capital structure remains stable. Recent events, including filings and transcripts, do not indicate any material changes in the company's operations or strategy. The company's management has not disclosed any significant new product launches or strategic acquisitions in the latest quarterly reports. Analysts have a generally positive outlook, with a mean recommendation of 2.57 (1=strong buy, 5=strong sell), and a mean price target of INR 1,455.11.